Fresenius Kabi Pharmaceuticals Holding, Inc. Announces Filing of Form 10-Q

SCHAUMBURG, Ill.--(Business Wire)--
Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) announced today
that it has filed its Form 10-Q with the Securities and Exchange Commission.
Fresenius Kabi Pharmaceuticals Holding, Inc., acquired APP Pharmaceuticals,
Inc., on September 10, 2008. The Form 10-Q details the Company`s unaudited
financial statements for the quarter ending March 31, 2009.

The Form 10-Q has been posted to APP`s Web site at www.APPpharma.com and is also
available at the Securities and Exchange Commission`s Web site at www.SEC.gov.

About APP Pharmaceuticals, Inc.

APP Pharmaceuticals, Inc. is a fully-integrated pharmaceutical company that
develops, manufactures and markets injectable pharmaceutical products with a
primary focus on the oncology, anti-infective, anesthetic/analgesic and critical
care markets. The company offers one of the most comprehensive product
portfolios used in hospitals, long-term care facilities, alternate care sites
and clinics within North America and manufactures a comprehensive range of
dosage formulations. Fresenius Kabi Pharmaceuticals Holding, Inc., a wholly
owned subsidiary of Fresenius Kabi AG, acquired APP Pharmaceuticals, Inc. on
September 10, 2008. For more information about APP Pharmaceuticals, Inc., please
visit the company`s Web site at www.APPpharma.com.

About Fresenius Kabi AG

Fresenius Kabi AG is the leader in infusion therapy and clinical nutrition in
Europe and in its most important countries of Latin America and Asia Pacific.
Fresenius Kabi`s core product range includes infusion solutions for fluid
substitution, blood volume expansion, I.V. drugs and parenteral nutrition, as
well as products for enteral nutrition. Furthermore, the company provides
concepts for ambulatory health care and is focused on managing and providing
home therapies. With the philosophy "Caring for life" and a comprehensive
product portfolio, the company aims at improving the quality of life of patients
all over the world. In 2008, Fresenius Kabi achieved sales of EUR 2,495 million
and an operating profit of EUR 443 million. For more information visit the
company`s Web site at www.fresenius-kabi.com. Fresenius Kabi AG is a 100%
subsidiary of Fresenius SE. Fresenius SE is a health care group with
international operations, providing products and services for dialysis, hospital
and outpatient medical care. In 2008, group sales were approximately EUR 12.3
billion. For more information visit the company`s Web site at www.fresenius.com.

Forward-Looking Statement

The statements contained in this news release that are not purely historical are
forward-looking statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking statements in this news
release include statements regarding our expectations, beliefs, hopes, goals,
intentions, initiatives or strategies, including statements regarding the
demand, supply and distribution of our products. Because these forward-looking
statements involve risks and uncertainties, there are important factors that
could cause actual results to differ materially from those in the
forward-looking statements. These factors include, but are not limited to, the
availability and pricing of ingredients used in the manufacture of
pharmaceutical products and the ability to successfully manufacture products in
a time-sensitive and cost effective manner. Additional relevant information
concerning risks can be found in the Fresenius Kabi Pharmaceuticals Holding,
Inc. 10-K for the fiscal year ending December 31, 2008 and other documents the
company has filed with the Securities and Exchange Commission.

The information contained in this news release is as of the date of this
release. Fresenius Kabi Pharmaceuticals Holding, Inc. does not assume any
obligation to update or revise these forward-looking statements to conform the
statement to actual results, new information, developments or changes in the
Company`s expectations.

APP Contact
APP Pharmaceuticals, Inc.
Debra Lynn Ross
Director, Corporate Communications
(847) 969-8026
dross@apppharma.com
or
Investor and Media Inquiries
Hill & Knowlton
Christine Cassiano
(310) 633-9495
christine.cassiano@hillandknowlton.com

Copyright Business Wire 2009